Literature DB >> 11487512

The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs.

D J Williamson1, R G Hill, S L Shepheard, R J Hargreaves.   

Abstract

These studies investigated the pharmacology of neurogenic dural vasodilation in anaesthetized guinea-pigs. Following introduction of a closed cranial window the meningeal (dural) blood vessels were visualized using intravital microscopy and the diameter constantly measured using a video dimension analyser. Dural blood vessels were constricted with endothelin-1 (3 microg kg(-1), i.v.) prior to dilation of the dural blood vessels with calcitonin gene-related peptide (CGRP; 1 microg kg(-1), i.v.) or local electrical stimulation (up to 300 microA) of the dura mater. In guinea-pigs pre-treated with the CGRP receptor antagonist CGRP((8-37)) (0.3 mg kg(-1), i.v.) the dilator response to electrical stimulation was inhibited by 85% indicating an important role of CGRP in neurogenic dural vasodilation in this species. Neurogenic dural vasodilation was also blocked by the 5-HT(1B/1D) agonist rizatriptan (100 microg kg(-1)) with estimated plasma levels commensurate with concentrations required for anti-migraine efficacy in patients. Rizatriptan did not reverse the dural dilation evoked by CGRP indicating an action on presynaptic receptors located on trigeminal sensory fibres innervating dural blood vessels. In addition, neurogenic dural vasodilation was also blocked by the selective 5-HT(1D) agonist PNU-142633 (100 microg kg(-1)) but not by the 5-HT(1F) agonist LY334370 (3 mg kg(-1)) suggesting that rizatriptan blocks neurogenic vasodilation via an action on 5-HT(1D) receptors located on perivascular trigeminal nerves to inhibit CGRP release. This mechanism may underlie one of the anti-migraine actions of the triptan class exemplified by rizatriptan and suggests that the guinea-pig is an appropriate species in which to investigate the pharmacology of neurogenic dural vasodilation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11487512      PMCID: PMC1572868          DOI: 10.1038/sj.bjp.0704162

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  31 in total

1.  Differential effects of 5-HT1B/1D receptor agonists on neurogenic dural plasma extravasation and vasodilation in anaesthetized rats.

Authors:  S L Shepherd; D J Williamson; M S Beer; R G Hill; R J Hargreaves
Journal:  Neuropharmacology       Date:  1997 Apr-May       Impact factor: 5.250

2.  Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat--intravital microscope studies.

Authors:  D J Williamson; R J Hargreaves; R G Hill; S L Shepheard
Journal:  Cephalalgia       Date:  1997-06       Impact factor: 6.292

3.  Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural vessel diameter in the anaesthetized rat.

Authors:  D J Williamson; R J Hargreaves; R G Hill; S L Shepheard
Journal:  Cephalalgia       Date:  1997-06       Impact factor: 6.292

4.  The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation.

Authors:  D J Williamson; S L Shepheard; R G Hill; R J Hargreaves
Journal:  Eur J Pharmacol       Date:  1997-06-05       Impact factor: 4.432

5.  Cardiovascular effects of cholecystokinin-4 are mediated by the cholecystokinin-B receptor subtype in the conscious guinea pig and dog.

Authors:  A A Fossa; M J DePasquale; J Morrone; S H Zorn; D Bryce; J A Lowe; S McLean
Journal:  J Pharmacol Exp Ther       Date:  1997-04       Impact factor: 4.030

6.  Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels.

Authors:  I Bouchelet; Z Cohen; B Case; P Séguéla; E Hamel
Journal:  Mol Pharmacol       Date:  1996-08       Impact factor: 4.436

7.  Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks.

Authors:  A May; H J Gijsman; A Wallnöfer; R Jones; H C Diener; M D Ferrari
Journal:  Pain       Date:  1996-10       Impact factor: 6.961

8.  The influence of the trigeminal ganglion on carotid blood flow in anaesthetized guinea-pigs.

Authors:  D T Beattie; H E Connor
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

9.  Selective 5-HT1D alpha serotonin receptor gene expression in trigeminal ganglia: implications for antimigraine drug development.

Authors:  G W Rebeck; K I Maynard; B T Hyman; M A Moskowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

10.  5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs.

Authors:  K W Johnson; J M Schaus; M M Durkin; J E Audia; S W Kaldor; M E Flaugh; N Adham; J M Zgombick; M L Cohen; T A Branchek; L A Phebus
Journal:  Neuroreport       Date:  1997-07-07       Impact factor: 1.837

View more
  14 in total

1.  Inhibitory effect of BIBN4096BS, CGRP(8-37), a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery.

Authors:  L Edvinsson; E Nilsson; I Jansen-Olesen
Journal:  Br J Pharmacol       Date:  2007-01-22       Impact factor: 8.739

2.  Effect of intra-arterial injection of lidocaine and methyl-prednisolone into middle meningeal artery on intractable headaches.

Authors:  Adnan I Qureshi; Mushtaq H Qureshi; Asif A Khan; M Fareed K Suri
Journal:  J Vasc Interv Neurol       Date:  2014-12

Review 3.  Modelling headache and migraine and its pharmacological manipulation.

Authors:  S E Erdener; T Dalkara
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

4.  Pharmacology.

Authors:  Hayrunnisa Bolay; Paul Durham
Journal:  Handb Clin Neurol       Date:  2010

5.  5-HT7 receptors are involved in neurogenic dural vasodilatation in an experimental model of migraine.

Authors:  Xiaojuan Wang; Yannan Fang; Jianbo Liang; Miansheng Yan; Rong Hu; Xiaoping Pan
Journal:  J Mol Neurosci       Date:  2014-03-02       Impact factor: 3.444

Review 6.  Spotlight on rizatriptan in migraine.

Authors:  Keri Wellington; Blair Jarvis
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 7.  Rizatriptan: an update of its use in the management of migraine.

Authors:  Keri Wellington; Greg L Plosker
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  Characterization of opioid receptors that modulate nociceptive neurotransmission in the trigeminocervical complex.

Authors:  R J Storer; S Akerman; P J Goadsby
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

Review 9.  CGRP in Animal Models of Migraine.

Authors:  Anne-Sophie Wattiez; Mengya Wang; Andrew F Russo
Journal:  Handb Exp Pharmacol       Date:  2019

10.  Targeting the central projection of the dural trigeminovascular system for migraine prophylaxis.

Authors:  Simon Akerman; Marcela Romero-Reyes
Journal:  J Cereb Blood Flow Metab       Date:  2017-09-08       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.